Search

Displaying results 2931 - 2940 of 5900 in total
  1. Drug

    Etonogestrel

    go.drugbank.com/drugs/DB00294
    ApprovedInvestigational

    Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel. The first product including etonogestrel was developed by the Merck subsidiary Organon and F...

  2. Drug

    Etryptamine

    go.drugbank.com/drugs/DB01546
    ApprovedIllicitWithdrawn

    Similarly to MDMA, αET has been shown to release serotonin pre-synaptically, as well as lesser amounts of norepinephrine and dopamine. … In 1993, the US Drug Enforcement Administration added αET to Schedule I of its Schedules of Controlled Substances, after an increasing incidence of its use as a recreational drug in the 1980's.

  3. Drug

    Iodamide

    go.drugbank.com/drugs/DB08948
    ApprovedWithdrawn

    Iodamide is a contrast medium molecule that is no longer marketed in the United States.

  4. Drug

    Relatlimab

    go.drugbank.com/drugs/DB14851
    ApprovedInvestigational

    [L41265,L41300] It was the first anti-LAG-3 antibody to demonstrate benefit in a Phase 3 study, as well as the first to receive FDA approval. … efficacy when used alone, drugs like relatlimab have been trialed in combination with other checkpoint inhibitors - for example, PD-1 inhibitors like [nivolumab] or CTLA-4 inhibitors like [ipilimumab] - to

  5. Drug

    Taurolidine

    go.drugbank.com/drugs/DB12473
    ApprovedInvestigational

    Taurolidine is an antimicrobial used for the prevention of catheter-related infections. It is a derivative of the amino acid taurine. It was first synthesized in the 1970s and was originally used as a prophylactic against intraperitoneal...

  6. Drug

    Curcuma aromatica root oil

    go.drugbank.com/drugs/DB11301
    Approved

    Curcuma aromatica root oil is also suggested to have antibacterial activity. … The major constituents of Curcuma aromatica root oil are reported to be camphor, curzerenone, α-turmerone, ar-turmerone and 1,8-cineole [A27219].

  7. Drug

    Ipilimumab

    go.drugbank.com/drugs/DB06186
    ApprovedInvestigational

    Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol...

  8. Drug

    Asfotase alfa

    go.drugbank.com/drugs/DB09105
    ApprovedInvestigational

    By replacing deficient ALP, treatment with Asfotase Alfa aims to improve the elevated enzyme substrate levels and improve the body's ability to mineralize bone, thereby preventing serious skeletal and … Asfotase alfa is a first-in-class bone-targeted enzyme replacement therapy designed to address the underlying cause of hypophosphatasia (HPP)—deficient alkaline phosphatase (ALP).

  9. Drug

    Pentamidine

    go.drugbank.com/drugs/DB00738
    ApprovedInvestigational

    Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other t...

  10. Drug

    Eravacycline

    go.drugbank.com/drugs/DB12329
    ApprovedInvestigational

    Eravacycline has demonstrated superior potency to that of antibiotics that are currently being marketed for intraabdominal infections [A38727]. … This includes most of those bacteria resistant to cephalosporins, fluoroquinolones, β-lactam/β-lactamase inhibitors, multidrug-resistant strains, and carbapenem-resistant Enterobacteriaceae, and the majority